Erasca, Inc. - Common Stock (ERAS)

Frequently Asked Questions About Erasca, Inc. - Common Stock (ERAS)

How can investors stay updated about Erasca, Inc.?

Investors can stay updated about Erasca, Inc. by following the company's official website, subscribing to press releases, and monitoring financial news platforms. Additionally, they can participate in investor forums and attend industry conferences where executives may provide updates on the company's progress.

How does Erasca, Inc. fund its operations?

Erasca, Inc. funds its operations primarily through equity financing, including Initial Public Offerings (IPOs) and subsequent public offerings of common stock. The company may also seek grants, partnerships, and collaborations with other biotech or pharmaceutical companies to support its research and development initiatives.

How has Erasca, Inc. performed financially in recent years?

Erasca, Inc.'s financial performance can be evaluated through its financial statements, which outline its revenues, expenses, and cash flows. The company's focus on research and development often results in higher expenditures, but its strategy aims toward long-term growth as it advances its clinical programs.

Is Erasca, Inc. involved in any partnerships or collaborations?

Yes, Erasca, Inc. actively seeks partnerships and collaborations with other organizations in the biotech and pharmaceutical industries. These alliances can enhance its drug development capabilities by providing access to additional resources, expertise, and technology.

What are Erasca's main therapeutic areas?

Erasca, Inc. primarily focuses on oncology, particularly on developing therapies for patients with solid tumors and specific genetic alterations. By concentrating on precision medicine, the company seeks to improve treatment outcomes for individuals suffering from various forms of cancer.

What are Erasca's most notable product candidates?

Erasca, Inc.'s most notable product candidates include therapies targeting specific oncogenic drivers in cancer, which are currently in various phases of clinical trials. These candidates are developed based on promising preclinical data and aim to provide focused treatment options for patients with particular genetic mutations.

What are the long-term goals of Erasca, Inc.?

Erasca, Inc.'s long-term goals include successfully advancing its pipeline of cancer therapies through clinical development, achieving regulatory approvals, and ultimately bringing innovative treatments to market that can significantly improve outcomes for patients with cancer.

What does Erasca, Inc. do?

Erasca, Inc. is a biotechnology company focused on developing innovative cancer therapies. The company aims to create and deliver precision medicines that target specific genetic drivers of cancer, utilizing its expertise in tumor biology and drug development. Erasca's pipeline includes multiple therapeutic candidates that are currently in various stages of clinical trials.

What is Erasca's approach to drug discovery?

Erasca employs a precision medicine approach to drug discovery, which involves identifying specific genetic drivers of cancer and designing therapies that selectively target these alterations. This strategy aims to enhance the effectiveness of treatments while minimizing side effects and improving patient outcomes.

What is the competitive landscape for Erasca, Inc.?

The competitive landscape for Erasca, Inc. includes numerous biotechnology firms focused on oncology and precision medicine. While there are several established players in the market, Erasca’s unique approach to targeting specific genetic mutations grants it a competitive edge in the race for innovative cancer therapies.

What is the current status of Erasca's clinical trials?

Erasca, Inc. has several clinical trials underway for its drug candidates. The company frequently updates the public about the progress of these trials, including phases of development, patient enrollment status, and preliminary results through press releases and its corporate website.

What is the leadership team like at Erasca, Inc.?

Erasca, Inc. has a diverse and experienced leadership team, composed of professionals with a strong background in biotechnology, oncology, and business development. This team is committed to guiding the company toward its mission of developing effective cancer therapies through innovation and collaboration.

What is the stock symbol for Erasca, Inc.?

The stock symbol for Erasca, Inc. is ERAS, and it trades on the Nasdaq stock exchange. The company's listing provides it with the ability to access public markets for funding and to create greater visibility within the investment community.

What makes Erasca, Inc. unique in the biotech industry?

Erasca, Inc. distinguishes itself in the biotech industry through its exclusive focus on precision oncology, leveraging advanced technologies and deep scientific insights to develop targeted therapies. The company's commitment to addressing specific genetic drivers of cancer allows it to pursue unmet medical needs effectively.

What recent events have impacted Erasca, Inc.?

Recent events impacting Erasca, Inc. may include patient enrollment updates, clinical trial results, regulatory submissions, or potential partnerships and collaborations within the biotech sector. The company often shares these developments through press releases and financial disclosures.

When was Erasca, Inc. founded?

Erasca, Inc. was founded in 2018. Since its inception, the company has focused on addressing significant unmet medical needs in oncology by developing targeted therapies aimed at treating patients with specific genetic abnormalities in their tumors.

Where is Erasca, Inc. headquartered?

Erasca, Inc. is headquartered in San Diego, California. This location places the company in a vibrant biotech hub, allowing for access to a wide network of industry expertise, partnerships, and investment opportunities.

Who are the founders of Erasca, Inc.?

Erasca, Inc. was co-founded by Dr. Andrew J. Allen and a team of experienced professionals in the biotech industry. The founders bring a wealth of expertise in cancer research, drug development, and clinical operations, which drives the company's vision and strategic goals.

What is the current price of Erasca, Inc. - Common Stock?

The current price of Erasca, Inc. - Common Stock is 2.780

When was Erasca, Inc. - Common Stock last traded?

The last trade of Erasca, Inc. - Common Stock was at 4:00 pm EST on November 20th, 2025

What is the market capitalization of Erasca, Inc. - Common Stock?

The market capitalization of Erasca, Inc. - Common Stock is 419.90M

How many shares of Erasca, Inc. - Common Stock are outstanding?

Erasca, Inc. - Common Stock has 151.04M shares outstanding.